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Abstract
Aims/hypothesis Actin and focal adhesion (FA) remodelling
are essential for glucose-stimulated insulin secretion (GSIS).
Non-muscle myosin II (NM II) isoforms have been implicated
in such remodelling in other cell types, and myosin light chain
kinase (MLCK) and Rho-associated coiled-coil-containing ki-
nase (ROCK) are upstream regulators of NM II, which is known
to be involved in GSIS. The aim of this work was to elucidate
the implication and regulation of NM IIA and IIB in beta cell
actin and FA remodelling, granule trafficking and GSIS.
Methods Inhibitors of MLCK, ROCK and NM II were used
to study NM II activity, and knockdown of NM IIA and IIB
to determine isoform specificity, using sorted primary rat
beta cells. Insulin was measured by radioimmunoassay.
Protein phosphorylation and subcellular distribution were
determined by western blot and confocal immunofluores-
cence. Dynamic changes were monitored by live cell imag-
ing and total internal reflection fluorescence microscopy
using MIN6B1 cells.
Results NM II and MLCK inhibition decreased GSIS, asso-
ciated with shortening of peripheral actin stress fibres, and
reduced numbers of FAs and insulin granules in close prox-
imity to the basal membrane. By contrast, ROCK inhibition
increased GSIS and caused disassembly of glucose-induced
central actin stress fibres, resulting in large FAs without any
effect on FA number. Only glucose-induced NM IIA reor-
ganisation was blunted by MLCK inhibition. NM IIA
knockdown decreased GSIS, levels of FA proteins and
glucose-induced extracellular signal-regulated kinase 1/2
phosphorylation.
Conclusions/interpretation Our data indicate that MLCK–
NM IIA may modulate translocation of secretory granules,
resulting in enhanced insulin secretion through actin and FA
remodelling, and regulation of FA protein levels.
Keywords Actin remodelling . Beta cell . Focal adhesion .
Insulin secretion . Non-muscle myosin II
Abbreviations
ECM Extracellular matrix
ERK Extracellular signal-regulated kinase
FA Focal adhesion
F-actin Filamentous actin
FAK Focal adhesion protein kinase
GFP Green fluorescent protein
GSIS Glucose-stimulated insulin secretion
MHC Myosin heavy chain
MLC Myosin light chain
MLCK Myosin light chain kinase
NM II Non-muscle myosin II
NPY Neuropeptide Y
PAX Paxillin
ROCK Rho-associated coiled-coil-containing kinase
siRNA Short interfering RNA
TIRF Total internal reflection fluorescence
Introduction
The pathogenesis of beta cell dysfunction in type 2 diabetes
is characterised by progressive loss of beta cell function and
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mass [1]. A better understanding of the beta cell secretory
pathway might reveal new targets for the treatment of type 2
diabetes. Filamentous actin (F-actin) and focal adhesion
(FA) remodelling in beta cells play a crucial role in insulin
secretion [2, 3]. In beta cells, glucose-stimulated insulin
secretion (GSIS) is triggered by phosphorylation and acti-
vation of focal adhesion protein kinase (FAK) and paxillin
(PAX), and their recruitment into nascent lamellipodia
linked to the activation of extracellular signal-regulated
kinase (ERK) 1/2 through β1-integrin engaged with the
extracellular matrix (ECM) [2–4]. F-actin reorganisation
following glucose stimulation is a prerequisite for FA for-
mation, allowing insulin granules to approach the plasma
membrane and engage with components of the exocytotic
machinery for docking and fusion [2, 4, 5]. A recent in vivo
study using a beta cell-specific FAK knockout mouse con-
firmed these in vitro findings and further demonstrated a key
role for FAK in beta cell viability through insulin signalling
[6]. Nevertheless, the detailed regulation of FA and actin
remodelling in beta cells, and the key molecules that couple
this to GSIS, remain to be elucidated.
Non-muscle myosin II (NM II) is a major cytoskeletal
protein that interacts with F-actin to contribute to cellular
processes, such as migration and adhesion [7]. NM II has a
functional role in FA and actin remodelling [7–9], and has
been implicated in late events leading to exocytosis in other
secretory cells [10, 11]. Previous studies have suggested that
NM II could be an actin-motor protein implicated in insulin
secretion [12, 13]. NM II consists of two myosin heavy chains
(MHC), two essential light chains and two regulatory light
chains (MLC). In mammals, three different genes encode NM
II proteins, including MHC IIA (Myh9) and IIB (Myh10).
These isoforms exhibit different enzymatic properties, subcel-
lular localisation and tissue patterns [14–16], leading us to
postulate isoform-specific roles in beta cell secretion. MHC
IIA contributes to FA stability and maturation [17–19] and to
Rho-associated coiled-coil-containing kinase (ROCK)-depen-
dent functions including stress fibre organisation [20].
Furthermore, this isoform associates with actin fibres follow-
ing KCl stimulation of RINm5F cells [13], suggesting a
possible role in exocytosis. MHC IIB contributes to cell
migration by controlling protrusion stability and also mediates
stress fibre formation [21, 22].
Unlike other myosins, NM II is regulated by direct phos-
phorylation of both its heavy and light chains. Myosin light
chain kinase (MLCK) and ROCK activate NM II through
MLC phosphorylation, which induces FA maturation and
contributes to F-actin polymerisation in stress fibres [7, 23].
In beta cells, Rho–ROCK signalling contributes to the sta-
bilisation of the actin cytoskeleton and inhibits GSIS [24],
while MLCK co-localises with insulin granules [25]. Other
studies correlated insulin secretion with MHC phosphoryla-
tion and revealed co-localisation with F-actin [13, 26];
heavy chain phosphorylation seemed to be more impor-
tant for insulin secretion than regulatory light chain
phosphorylation. MLC phosphorylation by ROCK occurs
centrally, and by MLCK towards the periphery, with distinct
effects on plasma membrane ruffling and FA dynamics in
fibroblasts [27].
We have studied the role of NM II isoforms and their
upstream regulators MLCK and ROCK in beta cell function.
We highlight the MLCK–MHC IIA–FAK–PAX–ERK path-
way as a positive regulator of insulin secretion. MHC IIA
emerges as a central regulatory molecule that serves to
integrate and coordinate actin and FA remodelling, secretory
signalling pathways and granule shuttling to the basal mem-
brane, all key components of GSIS.
Methods
Antibodies and reagents anti-FAK: Santa Cruz Biotechnology
(Santa Cruz, CA, USA); -phospho(Y397)-FAK and -phospho
(Y118)-paxillin: Invitrogen (Carlsbad, CA, USA); -paxillin: BD
Transduction Laboratories (San Jose, CA, USA); -ERK1/2, -
phospho(T202/Y204)-ERK1/2 and -actin: Cell Signaling
Technology (Beverly, MA, USA); -γ-actin: a gift from C.
Chaponnier (University of Geneva, Geneva, Switzerland); -
MHC IIA and -MHC IIB: Covance Research Products
(Emeryville, CA, USA); donkey anti-rabbit horseradish perox-
idase (HRP) and sheep anti-mouse HRP: Amersham
Biosciences (Uppsala, Sweden); donkey anti-rabbit Alexa
Fluor 488 and donkey anti-mouse Alexa Fluor 555, Alexa
Fluor 647-phalloidin: Invitrogen; Y-27362 and blebbistatin:
Calbiochem (La Jolla, CA, USA); ML7: Sigma Chemical
Company (St Louis, MO, USA).
Cells and culture conditions Rat islet isolation, beta cell
sorting by FACS and monolayer culture on ECM from
804G cells (804G-ECM) were performed as previously de-
scribed [28]. MIN6B1 cells were cultured as previously
described [29] and plated on 35 mm glass-bottomed micro-
well dishes (MatTek, Ashland, MA, USA) coated with
804G-ECM for total internal reflection fluorescence (TIRF)
microscopy and confocal live imaging [30].
Expression vectors The pEGFPC1-FAK plasmid was a gift
from D. D. Schlaepfer (University of California, San Diego,
CA, USA); paxillin-pEGFP was from AddGene (Cambridge,
MA, USA); and neuropeptide Y (NPY)-Cherry was a gift
from G. Rutter (Imperial College London, London, UK).
Ribonucleic acid interference-mediated silencing of MHC
IIA and IIB MHC IIA and IIB levels were knocked down by
transfecting primary rat beta cells twice with two specific
short interfering RNA molecules (siRNAs) directed towards
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rat MHC IIA or IIB messenger ribonucleic acid (electronic
supplementary material [ESM] Table 1) (Microsynth AG,
Balgach, Switzerland), using Lipofectamine 2000 reagent
(Invitrogen) according to the manufacturer’s instructions.
Transfected cells were incubated for 72 h to allow siRNA
expression before cell treatment and analysis.
SDS-PAGE and western blotting Protein samples were pre-
pared and immunoblots analysed as described [2]. Western
blots were quantified by densitometry and band density of
phosphoproteins normalised to that of the corresponding
total protein and/or to total actin as indicated in the figure
legends.
TIRF microscopy Cells were transfected using Lipofectamine
2000 reagent according to the manufacturer’s instructions and
incubated for 48 h to allow for DNA expression. TIRF images
were obtained as earlier described [3].
Immunof luorescence and con foca l microscopy
Immunofluorescence was performed as previously de-
scribed [4]. Cell basal membranes were observed by confo-
cal microscopy using a Zeiss LSM510 Meta microscope
with a ×63 oil immersion lens, and the images were acquired
and processed using LSM510 software (Carl Zeiss, Iena,
Germany). Confocal live imaging was performed with a
Nikon A1r microscope (Nikon, Tokyo, Japan) equipped
with a ×60 CFI plan Apo objective and a filter optimised
for mCherry fluorescence. Cells on 804G-coated glass-
bottomed culture dishes were maintained on the microscope
stage at 37°C and 5% CO2. Transfected cells were chosen at
random for analysis, and images were captured every 60 s.
Insulin secretion assays Rat beta cells were washed, pre-
incubated and incubated for insulin secretion assays, and
insulin was measured by radioimmunoassay as previously
described [4].
Statistical analysis Statistical significance for differences
between experimental conditions was determined using
GraphPad Prism version 5.00 for Windows, (GraphPad
Software, San Diego, USA) by one-way ANOVA when
more than two conditions were compared and by Student’s
t test for unpaired groups for comparison of two conditions;
p values less than 0.05 were considered significant.
Results
Impact of NM II function on GSIS in rat primary beta
cells Various inhibitors were used to study the impact of
NM II and its upstream regulators MLCK and ROCK on
GSIS: blebbistatin is a myosin II-specific ATPase inhibitor
that completely blocks enzyme activity [31]; ML7 is a
selective inhibitor of MLCK; Y27632 is an inhibitor of
ROCK. As shown in Fig. 1a, blebbistatin decreased GSIS
in a concentration-dependent manner without affecting basal
secretion. MLCK inhibition similarly decreased GSIS by
25.5±3.5% (p<0.05) without affecting basal secretion
(Fig. 1b). By contrast, ROCK inhibition (Y27632) increased
GSIS by 1.91±0.63-fold (data not shown), as previously
demonstrated by our group [24]. There was no effect of
the inhibitors on cellular insulin content (data not shown).
These results suggested that MLCK–NM II signalling
favours GSIS, whereas ROCK inhibits it, confirming the
opposing role of these two kinases on cell function [27, 32].
Impact of inhibition of MLCK, NM II and ROCK on actin
and FA remodelling in rat primary beta cells In view of the
important role of FA and F-actin reorganisation in the reg-
ulation of GSIS and the known role of NM II in such
reorganisation in other cell types, we next studied the effects
of MLCK, NM II and ROCK inhibition using confocal
immunofluorescence. ROCK inhibition by Y27632 revealed
F-actin filaments in the central portion of the cell, whereas
MLCK inhibition by ML7 led to the formation of actin
bundles at the cell periphery; both inhibitors induced mem-
brane protrusions compared with control conditions.
Blebbistatin completely modified cell morphology, includ-
ing formation of large blebs in the absence or presence of
high glucose, blunted glucose-induced actin reorganisation
and caused actin accumulation at the cell periphery
(Fig. 2a). Glucose stimulation led to bundling of F-actin
filaments and protrusion formation as previously demon-
strated [2]. Upon glucose stimulation, ROCK inhibition
caused disassembly of actin stress fibres in the central
portion of the cell without affecting those located in the
Fig. 1 Inhibition of myosin II and MLCK decreases GSIS. Cells were
pre-incubated for 2 h at 2.8 mmol/l glucose, and basal secretion was
measured during a further 1 h at the same glucose concentration in the
continued presence, or not (CTL), of an inhibitor ([a] 25 μmol/l or
50 μmol/l blebbistatin (BL), [b] 20 μmol/l ML7), and then stimulated
with high glucose (16.7 mmol/l) in the presence of the different
inhibitors for 1 h (white bars, basal; black bars, stimulated). Data
are mean±SEM from four independent experiments (t test, *p<0.05,
**p<0.01)
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periphery. However, MLCK inhibition seemed to have no
effect on central actin remodelling but caused shortening of
peripheral stress fibres (Fig. 2a).
Inhibition of MLCK and NM II caused profound changes
in the intracellular distribution of pY397FAK and PAX in both
basal and stimulated conditions (Fig. 2b), accompanied by a
54.1±5.1% (p<0.05) and 88.7±6.0% (p<0.01) decrease in
the number of glucose-induced FAs, respectively (Fig. 2c). By
contrast, ROCK inhibition induced large FAs containing
pY397FAK and PAX, and an increase in FA number in the
basal condition (2.8 mmol/l glucose), but was without signif-
icant effect after glucose stimulation (Fig. 2b, c).
MLCK inhibition blunts glucose-induced FAK, PAX and
ERK phosphorylation in rat primary beta cells To gain
insight into a possible effect of MLCK, NM II and ROCK
inhibition on the FAK signalling pathway, we studied the
impact of the inhibitors on the glucose-induced phosphory-
lation of FAK and two of its known downstream targets,
PAX and ERK1/2. FAK, PAX and ERK1/2 phosphorylation
induced by high glucose (16.7 mmol/l; 10 min) decreased in
the presence of ML7 by 43.5±3.8% (p<0.05), 40.9±22.7%
(p<0.05) and 64.3±14.6% (p<0.01), respectively (Fig. 3a–
c). There was no significant effect of blebbistatin because of
greater variability in the data. To obtain sufficient numbers,
MIN6B1 cells were used to monitor the time course of the
effects of blebbistatin. This highly differentiated mouse beta
cell line displays glucose-induced actin and FA remodelling
similar to primary rat beta cells [24]. This time course
showed a decrease in FAK, PAX and ERK1/2 phosphoryla-
tion in the presence of blebbistatin after 5 min of glucose
stimulation, which was completely restored after 10 min
(data not shown). The acute effects of blebbistatin on these
molecules appear short-lived, possibly explaining inter-
experimental variability at the 10 min time point studied
using primary cells. ROCK inhibition had no significant
effect on glucose-induced FAK, PAX and ERK phosphory-
lation (Fig. 3a–c). These results suggest other final effectors
in charge of the GSIS signalling pathway regulated by both
NM II and ROCK in an opposing way.
MLCK and myosin II are involved in granule movement and
localisation in MIN6B1 cells Following previous reports
indicating the involvement of actin remodelling and FA mat-
uration in dense-core vesicle transport and localisation close
to the basal membrane [3, 5], we investigated whether MLCK,
myosin II or ROCK inhibition affected the shuttling of insulin
granules and movement to the plasma membrane. Due to the
Fig. 2 Effect of the different
inhibitors on actin remodelling
and FA morphology and
number. Primary beta cells were
cultured for 3 h in low glucose
(2.8 mmol/l) in the presence, or
not (CTL), of an inhibitor
(25 μmol/l blebbistatin [BL],
20 μmol/l ML7 or 50 μmol/
l Y27632) and stimulated with
high glucose (16.7 mmol/l) for
10 min in the presence, or not,
of the respective inhibitor. (a)
Cells were subsequently fixed
and stained for actin (with
phalloidin) or (b) using anti-
pY397FAK (green) and PAX
(red). All images are fully rep-
resentative of four independent
experiments. (c) Cells were
subsequently fixed and stained
for pY397FAK. FAs containing
phosphorylated FAK were
counted in each cell (white bars,
2.8 mmol/l; black bars,
16.7 mmol/l). Data are mean±
SEM from three independent
experiments (one-way
ANOVA, *p<0.05, **p<0.01).
Scale bar, 10 μm
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low plasmid transfection rate in rat primary beta cells (less
than 5%), we performed TIRF and live microscopy in
MIN6B1 cells. Cells were transfected with a construct
expressing the fluorescent fusion protein NPY-Cherry to label
dense-core vesicles [33], FAK-green fluorescent protein
(GFP) and PAX-GFP. TIRF microscopy showed a reduction
in the number of plasma membrane-associated vesicles and
FA formation in glucose-stimulated conditions with ML7 or
blebbistatin (Fig. 4a). High glucose increased the number of
granules in close proximity to the plasma membrane, but this
was prevented by MLCK and NM II inhibition (Fig. 4b).
These data suggest that active MLCK–NM II is implicated
in glucose-induced delivery of insulin-containing granules to
the plasma membrane and FA formation. As anticipated,
ROCK inhibition did not affect the presence of insulin
granules and FA formation at the basal membrane
(Fig. 4a, b), confirming that MLCK–NM II and ROCK
regulate beta cell secretory function in an opposing way.
Fig. 3 ML7 inhibits glucose-induced FAK, PAX and ERK phosphor-
ylation in rat primary beta cells. Primary beta cells were cultured for
3 h in low glucose (2.8 mmol/l) in the presence, or not (CTL), of an
inhibitor (20 μmol/l ML7 or 50 μmol/l Y27632) and stimulated with
high glucose (16.7 mmol/l) for 10 min in the presence, or not, of the
respective inhibitor. Cell lysates were analysed by western blot, and the
relative intensities of phosphorylated (p) and total protein bands were
quantified by densitometry and expressed as a ratio in comparison with
non-stimulated control cells, and normalised to total actin (white bars,
2.8 mmol/l; black bars, 16.7 mmol/l). (a) pY397FAK/FAK total; (b)
pY118PAX/PAX total; (c) pT202/Y204 ERK1/2/ERK total. Data are
mean±SEM from three independent experiments (one-way ANOVA,
*p<0.05, **p<0.01)
Fig. 4 MLCK and myosin II are implicated in beta cell exocytosis.
MIN6B1 cells were co-transfected with NPY-Cherry, FAK-GFP and
PAX-GFP plasmids and cultured for 48 h in normal medium. Cells
were incubated with low glucose (2.8 mmol/l) in the presence, or not
(CTL), of an inhibitor (25 μmol/l blebbistatin [BL], 20 μmol/l ML7 or
50 μmol/l Y27632) for 3 h and stimulated with high glucose
(16.7 mmol/l) in the presence of the respective inhibitors for 10 min.
(a, b) The effect of the different inhibitors on insulin granule number at
the basal membrane was evaluated by TIRF microscopy on fixed cells.
(a) Representative pictures of each condition. Red corresponds to
dense-core insulin granules (NPY-Cherry) and green to FAK and
PAX protein tagged with GFP. (b) The number of secretory vesicles
detected by TIRF in the basal membrane and plasma membrane area
were quantified with ImageJ software 1.33u (NIH, Bethesda, MD,
USA) and expressed as a ratio of arbitrary units (white bar, 2.8 mmol/l;
black bars, 16.7 mmol/l). Data are means±SEM from three independent
experiments (one-way ANOVA, ***p<0.001). (c) Insulin granule move-
ment was observed in the presence of the different inhibitors using
confocal microscope live cell imaging. After transfection, cells were
treated without glucose in the presence, or not, of an inhibitor for 3 h
and stimulated with high glucose (20 mmol/l) in the presence, or not
(CTL), of inhibitors for 10 min. Pictures were taken every 5 s during
5 min (ESM Video 1 and ESM Video 2). All images are fully represen-
tative of three independent experiments. Scale bar, 10 μm
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The effect of NM II on granule movement was evaluated
by live confocal microscopy imaging of MIN6B1 cells
transfected with NPY-Cherry, FAK-GFP and PAX-GFP. In
Fig. 4c (see also ESM Videos 1, 2), control-stimulated cells
presented an important rate of insulin granule movement.
Blebbistatin completely blunted glucose-induced insulin
granule movement while dramatically altering the distribu-
tion of FAK and PAX (Fig. 4c). Y27632 failed to influence
granule movement to any apparent extent, contrary to ML7,
which seemed to induce a decrease in insulin granule velocity
(ESM Videos 1, 2).
MLCK inhibition blunts glucose-inducedMHC IIA remodelling,
and γ-actin protrusion formation and co-localisation with
MHC IIA at the cell periphery of rat primary beta cells In
view of the potential differential role of NM II isoforms in
beta cell function, we next examined the effect of glucose on
the distribution of the MHC of each isoform at the basal
surface of rat primary beta cells by immunofluorescence
using isoform-specific antibodies. As shown in Fig. 5a, b,
at low glucose, MHC IIA and IIB were concentrated at the
cell periphery and co-localised with F-actin with a more
diffuse signal towards the centre of the cells. Furthermore,
we observed co-localisation of MHC IIA and IIB with
PAX in the cytoplasm. Upon short-term glucose stimulation,
there was rapid reorganisation of both MHC IIA and IIB,
coinciding with actin co-localisation in filaments (Fig. 5a,
b). We did not observe co-localisation of PAX and MHC IIA
or MHC IIB at filopodial extensions, suggesting an indirect
role of MHC II on FA maturation and/or stabilisation.
We next examined the effect of MLCK, NM II and
ROCK inhibition on MHC IIA and IIB distribution. As
shown in Fig. 2a, ROCK inhibition caused disassembly of
central glucose-induced actin stress fibres and induced actin
concentration in FAs at the cell surface which co-localised
with both MHC IIA and PAX (Fig. 5a). MLCK inhibition
blunted the glucose effect on actomyosin IIA bundle forma-
tion, with an MHC IIA localisation similar to that of the low
glucose condition, suggesting involvement of this kinase in
glucose-induced MHC IIA remodelling. Analysis of MHC
IIB distribution after glucose stimulation revealed no effect
of MLCK and ROCK inhibition (Fig. 5b). Blebbistatin,
however, blunted glucose-induced remodelling of both
MHC IIA and MHC IIB in bundles with cytoplasmic local-
isation of both isoforms (Fig. 5a, b, lower pictures). Most
interestingly, this set of images indicates that only glucose-
induced MHC IIA reorganisation was blunted by MLCK
inhibition and confirmed that MLCK–myosin IIA seems to
Fig. 5 MLCK inhibition blunts
glucose-induced MHC IIA
remodelling, glucose-induced
γ-actin protrusion formation
and co-localisation with MHC
IIA at the cell periphery. Pri-
mary beta cell cells were cul-
tured for 3 h in low glucose
(2.8 mmol/l) in the presence, or
not, of inhibitors (25 μmol/l
blebbistatin [BL], 20 μmol/l
ML7 or 50 μmol/l Y27632) and
fixed or further stimulated with
16.7mmol/l glucose for 10min in
the presence, or not, of inhibitors
before fixation. Cells were sub-
sequently fixed and stained for
(a) MHC IIA or (b) MHC IIB
(green), actin (phalloidin in red)
and PAX (blue). (c) Cells were
stained using specific γ-actin
(red) and MHC IIA (green) anti-
bodies. All images are fully rep-
resentative of three independent
experiments. Scale bar, 10 μm
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be an important regulator of beta cell molecular modifica-
tion induced by glucose. Preliminary studies (n02; data not
shown) suggest that glucose-induced MHC IIA reorgan-
isation is Ca2+-dependent, since this was prevented by
the voltage-gated calcium channel blocker nifedipine
(10 μmol/l).
Phalloidin does not stain all F-actin pools [34] and also
fails to discriminate between actin isoforms. Since γ-actin
has been localised in protrusions in other cell types [35], we
investigated the effect of glucose and MLCK inhibition on
its distribution. As predicted, there was indeed an increase in
γ-actin-containing protrusions in response to glucose, and
co-localisation with MHC IIA filaments at the cell periph-
ery. MLCK inhibition induced a decrease in protrusions
containing γ-actin and its co-localisation with MHC IIA
filaments (Fig. 5c).
MHC IIA and IIB are necessary for glucose-induced actin
remodelling and PAX localisation in rat primary beta cell
protrusions In another strategy to discriminate between the
roles of each NM II isoform in beta cell function, isoform-
specific siRNAs were developed to characterise any
loss-of-function associated phenotype. Ribonucleic acid
interference-mediated silencing of NM II isoforms resulted
in a 30.9±4.2% (p<0.05) and 36.6±2.2% (p<0.01) reduc-
tion in protein levels of MHC IIA (Fig. 6a) and MHC IIB
(Fig. 6b), respectively. Co-transfection with siRNA against
the two isoforms resulted in a 31.3±6.3% (p<0.05) and
44.0±8.9% (p<0.05) decrease in MHC IIA and IIB protein
levels, respectively. We therefore decided not to include
the double knockdown in the following experiments be-
cause it clearly induced cell death (data not shown).
Immunofluorescence of actin and PAX demonstrated that
MHC IIA knockdown strongly disrupted glucose-induced
actin filaments and PAX recruitment to FAs without affect-
ing MHC IIB distribution (Fig. 6c). Knockdown of MHC
IIB had no influence on PAX-containing FA formation
induced by glucose but blunted actin reorganisation, albeit
with less impact than MHC IIA knockdown (Fig. 6d).
MHC IIA but not MHC IIB is necessary for insulin secretion
through the FAK–PAX–ERK pathway in rat primary beta
cells Our previous results suggest an involvement of the
MLCK–MHC IIA axis in beta cell exocytosis. In view of
this, we assessed insulin secretion (Fig. 7a) following
knockdown of each myosin II isoform. First, we verified
that scrambled siRNAs had no effect on GSIS, allowing
them to be used as the control condition. Interestingly,
Fig. 6 MHC IIA and IIB are necessary for glucose-induced actin
remodelling and PAX localisation in protrusions. Primary beta cells
were transfected with siRNA against MHC IIA (IIA siRNA) or MHC
IIB (IIB siRNA), or with a mixture of scrambled siRNAs designed for
each specific isoform siRNA (SCR) and maintained in culture for
4 days. Cells were then cultured for 3 h in low glucose (2.8 mmol/l)
and stimulated with high glucose (16.7 mmol/l) for 10 min. (a, b) Cell
lysates were analysed by western blot, and the relative intensities of
total protein MHC IIA and MHC IIB bands were quantified by densi-
tometry and expressed as a ratio in comparison with the scrambled
siRNA condition and normalised to total actin. Data are means±SEM
from five independent experiments (one-way ANOVA, *p<0.05, **p<
0.01). (c, d) After glucose stimulation, cells were fixed and stained for
MHC IIA (c) or MHC IIB (d), actin (phalloidin) and PAX. All images
are fully representative of three independent experiments
798 Diabetologia (2013) 56:792–802
GSIS was decreased by 42.3±8.03% (p<0.01) when MHC
IIA had been knocked down, but there was no such inhibi-
tion after MHC IIB knockdown. Furthermore, there was no
impact of either MHC isoform-specific siRNA on cellular
insulin content (data not shown). To determine whether
MHC IIA and/or IIB may regulate insulin secretion through
FA protein regulation and downstream signalling, we com-
pared the effect of MHC IIA and IIB knockdown on FAK,
PAX and ERK1/2 protein levels (Fig. 7b). Only MHC IIA
knockdown resulted in a decrease of FAK and PAX levels
by 27.6±8.9% and 16.7±4.5% (p<0.05), respectively. Total
ERK1/2 protein levels remained unchanged but there was a
decrease in phosphorylated ERK1/2 (Fig. 7b). Taken togeth-
er these results indicate that MHC IIA plays an important
role in GSIS through the regulation of FAK and PAX protein
levels and ERK phosphorylation necessary for FA maturation
in response to glucose.
Discussion
Our results indicate a central role for MHC IIA in beta cell
function, serving as a point of convergence between glucose-
induced actin and FA remodelling, and GSIS. NM II regulates
actin organisation as well as the subcellular localisation of two
key FA proteins, FAK and PAX, and is involved in granule
shuttling and movement to the basal membrane in response to
glucose. While glucose induces both MHC IIA and IIB to
bundle and co-localise with F-actin, only MHC IIA appears
critical for the regulation of FAs and GSIS. MLCK has been
shown to regulate NM II [36] and is also involved in the
regulation of GSIS. We now show that MLCK is involved
in FA formation and in glucose-induced remodelling of MHC
IIA, without affecting the IIB isoform. These results allowed
us to identify MLCK–myosin IIA–FAK–PAX–ERK as a new
pathway involved in the regulation of GSIS.
In other cell types, MLC phosphorylation by ROCK
occurs towards the centre of the cell, and by MLCK towards
the periphery, with distinct effects on plasma membrane
ruffling and FA dynamics [32]. In support of this, our find-
ings in beta cells indicate that ROCK appears to regulate
glucose-induced central actin filaments contrary to MLCK,
which regulates γ-actin protrusion and its co-localisation
with MHC IIA at the cell periphery. In fibroblasts, dynamic
turnover of peripheral FAs is mediated by MLC phosphor-
ylation through MLCK [32], and, in a similar fashion, ML7
inhibited glucose-induced FA formation and FA protein
phosphorylation at the periphery of the beta cells. By con-
trast, ROCK inhibition has no effect on the number of
glucose-induced peripheral FAs. MLCK is thus suggested
positively to regulate γ-actin protrusion and FA formation,
which are implicated in the activation of GSIS through NM
II remodelling. Numerous studies confirm the heteroge-
neous character and dynamics of FAs, with divergent func-
tions in response to an upstream stimulus depending on the
orderly recruitment of myriad proteins and adaptors centred
around FAK [36]. In rat primary beta cells, ROCK inhibition
increases GSIS but not basal secretion [24]. However, in the
present study there was no effect of ROCK inhibition on
peripheral FA number or FA protein phosphorylation fol-
lowing glucose stimulation. This suggests that FA composi-
tion and disposition, rather than number per se, govern
secretion, as described in previous reports [36, 37].
Fig. 7 MHC IIA but not MHC IIB is necessary for insulin secretion
through FAK–PAX–ERK. Primary beta cells were transfected with
siRNA against MHC IIA (IIA siRNA), MHC IIB (IIB siRNA) or
scrambled siRNAs (SCR) and maintained in culture for 4 days. (a)
Insulin secretion was measured in beta cells incubated with low glu-
cose (2.8 mmol/l) and stimulated with high glucose (16.7 mmol/l) for
1 h (see legend to Fig. 1). Data are expressed as the percentage of total
insulin content (white bars, basal; black bars, stimulated). (b) Cell
lysates were analysed by western blot, and the relative intensities of
FAK, PAX, ERK and phosphorylated (p) ERK were quantified by
densitometry and expressed as a ratio in comparison with the control
condition with scrambled siRNA and normalised to total actin. Data
are mean±SEM from four independent experiments (one-way
ANOVA, *p<0.05, **p<0.01)
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Myosin II activity is determined by phosphorylation of its
regulatory MLC by MLCK or ROCK [7]. Involvement of
MLCK in insulin secretion has been previously described
[25, 38], but our findings add a specific role for NM II.
We also observed that upon glucose stimulation MLCK
specifically regulates remodelling of MHC IIA, presumably
secondary to MLC phosphorylation. NM II regulation may
also occur directly through phosphorylation of heavy chains
but this remains controversial. A couple of interesting stud-
ies in beta cell lines have shown that MHC modifications do
play a major role in insulin secretion [26, 39]. The possible
interplay between MLC phosphorylation by MLCK and
MHC phosphorylation merits further investigation but is
beyond the scope of the present study.
Our results also point toward NM II as a mediator of
granule shuttling at the basal membrane. NM II could act
either directly on granule fusion or indirectly by regulation
of molecular mechanisms involved in secretion such as actin
and FA remodelling [37, 40]. Our results suggest that NM II
regulates glucose-induced exocytosis through actin remodel-
ling. As suggested by previous studies, secretory granules use
actomyosin filaments as ‘rails’ to move to the basal membrane
[41], but actomyosin could also act as a ‘barrier’ regulating
secretory granule pool accessibility to the membrane [42].
These two hypotheses are not mutually exclusive, particularly
since two insulin vesicle pools exist that are differentially
regulated through actin remodelling [43]. We show that glu-
cose induces MLCK-mediated formation of actomyosin IIA
filaments and that MLCK and NM II inhibition decreased
insulin granule movement and localisation at the basal mem-
brane. Our data suggest that insulin granules use actomyosin
II filamentous rails for movement towards the basal mem-
brane after glucose stimulation, with MLCK as an upstream
regulator. On the other hand, the inhibitory action of ROCK
on GSIS [24] and the disassembly of central actin stress fibres
induced by Y27632 suggest that ROCK probably controls
central actin remodelling to restrain insulin granule access
towards the membrane. NM II could also recruit FA proteins
to the basal membrane, albeit without direct interaction be-
tween PAX andMHC II. Surprisingly, we show thatMHC IIA
is also involved in the regulation of FAK and PAX protein
levels. As previously observed in other secretory cells [40],
these data suggest a role for actomyosin II in the transport of
insulin granules to the plasma membrane also through the
regulation of FA formation and FA protein levels in beta cells.
Some cellular functions of NM II are isoform-specific,
whereas others are redundant [36]. MHC IIA has been
suggested to have a major role in GSIS [13]. We hereby
confirm this and provide a novel insight into its mode of
action. Although both isoforms regulate glucose-induced
actin remodelling, only MHC IIA controls GSIS, FA forma-
tion, and FAK and PAX protein levels without compensato-
ry or additive effects between the two isoforms. While each
isoform may thus be subject to differential regulation and/or
impact on different downstream pathways in beta cells,
MHC IIA is involved in two essential secretory processes:
it is an upstream regulator of the FA signalling pathway and
modulates actin remodelling upon glucose stimulation.
We show that glucose-induced activation of the MLCK–
MHC IIA–FAK–PAX–ERK signalling pathway promotes
insulin secretion, leading to the hypothesis that this pathway
may be perturbed in type 2 diabetes. Although there is
decreased beta cell mass in type 2 diabetes [44], this prob-
ably does not account for the observed beta cell dysfunction,
suggesting another mechanism [1]. Most recently, it has
been proposed that the decrease in insulin-positive cells in
type 2 diabetes is due to beta cell dedifferentiation and
reversion to progenitor-like cells [45]. Although involve-
ment of NM in dedifferentiation is poorly documented,
non-muscle MHC is used as a marker of dedifferentiation
in vascular smooth muscle cells [46], and NM II production
is upregulated during differentiation of mesenchymal stem
cells [19, 47]. Analysis of NM II isoform levels and activity
in type 2 diabetic beta cells and their potential role in beta
cell failure thus warrants further investigation.
In conclusion, NM II manages several major processes
involved in the beta cell response to glucose, including γ-
actin protrusion and remodelling, FA assembly and turn-
over, and the secretory granule approach to the basal mem-
brane. Our findings thereby further identify MHC IIA as a
master regulator of beta cell secretory function.
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